
|Articles|May 27, 2004
Docetaxel is approved for advanced prostate Ca
Docetaxel (Taxotere) has been approved by the FDA for the treatment of hormone-refractory metastatic prostate cancer when used in combination with prednisone.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











